📰 Medication Guide News
Page 34 - Medication Guide News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Medication Guide. Real-time updates on events, politics, business and more.
October 21, 2022
RINVOQ is now approved as the first and only oral JAK inhibitor for adults with active non-radiographic axial spondyloarthritis (nr-axSpA)RINVOQ i...
October 19, 2022
Data served as basis for recent FDA approval of ruxolitinib cream (Opzelura) 1.5% for the topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older Fifty-two
October 18, 2022
Helsinn publishes new data evaluating chlormethine gel's mode of action in Dermatology and Therapy Lugano, Switzerland, October 18, 2022 - Helsinn Group ("Helsinn"), a fully integrated, global
October 12, 2022
Companies on track to report data from the ongoing Phase 2 trial of mRNA-4157/V940 in combination with KEYTRUDA® as adjuvant therapy in high-risk melanoma in 4Q 2022CAMBRIDGE, MA and RAHWAY, NJ / ACCESSWIRE
October 12, 2022
Investegate announcements from Moderna Inc, Merck and Moderna Announce Exercise of Option
October 10, 2022
The rate of clinical remission was 47.9 percent in patients who received combination induction therapy with guselkumab and golimumab compared with either treatment alone at 38 weeks1 ... | October 10, 2022
October 5, 2022
Adzenys XR-ODT is FDA-Approved as Bioequivalent to Adderall XRReported Supply Disruptions of Adderall XR Generic Equivalents Have the Potential to Affect Patient Access to ADHD MedicationsENGLEWOOD, CO
September 29, 2022
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Presents New Long-Term Data from L-MIND Suggesting Durable Response to Treatment with Monjuvi® (tafasitamab-cxix) for Patients with R/R DLBCL 28.09.2022 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media Release BOS...
September 29, 2022
BOSTON - MorphoSys USA, Inc., a fully owned subsidiary of MorphoSys AG , announced data from the ongoing L-MIND study showing that Monjuvi plus lenalidomide followed by Monjuvi monotherapy provided... | September 29, 2022
September 28, 2022
The findings, including data from patients treated with the targeted immunotherapy for 5 years or more, will be presented during the Tenth Annual Meet